Literature DB >> 27208770

Drug-Resistant Tuberculosis: Challenges and Progress.

Sebastian G Kurz1, Jennifer J Furin2, Charles M Bark3.   

Abstract

Antimicrobial resistance is a natural evolutionary process, which in the case of Mycobacterium tuberculosis is based on spontaneous chromosomal mutations, meaning that well-designed combination drug regimens provided under supervised therapy will prevent the emergence of drug-resistant strains. Unfortunately, limited resources, poverty, and neglect have led to the emergence of drug-resistant tuberculosis throughout the world. The international community has responded with financial and scientific support, leading to new rapid diagnostics, new drugs and regimens in advanced clinical development, and an increasingly sophisticated understanding of resistance mechanisms and their application to all aspects of TB control and treatment.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antimicrobial resistance; Drug-resistant tuberculosis; Mycobacterium tuberculosis

Mesh:

Substances:

Year:  2016        PMID: 27208770      PMCID: PMC4876017          DOI: 10.1016/j.idc.2016.02.010

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  69 in total

1.  Access sought to tuberculosis drug from nutraceutical company.

Authors:  Karl Gruber
Journal:  Nat Med       Date:  2015-02-02       Impact factor: 53.440

2.  STREPTOMYCIN treatment of pulmonary tuberculosis.

Authors: 
Journal:  Br Med J       Date:  1948-10-30

3.  Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB.

Authors:  Saverio De Lorenzo; Jan Wilem Alffenaar; Giovanni Sotgiu; Rosella Centis; Lia D'Ambrosio; Simon Tiberi; Mathieu S Bolhuis; Richard van Altena; Piero Viggiani; Andrea Piana; Antonio Spanevello; Giovanni Battista Migliori
Journal:  Eur Respir J       Date:  2012-09-20       Impact factor: 16.671

4.  Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis.

Authors:  Lukas Fenner; Matthias Egger; Thomas Bodmer; Ekkehardt Altpeter; Marcel Zwahlen; Katia Jaton; Gaby E Pfyffer; Sonia Borrell; Olivier Dubuis; Thomas Bruderer; Hans H Siegrist; Hansjakob Furrer; Alexandra Calmy; Jan Fehr; Jesica Mazza Stalder; Béatrice Ninet; Erik C Böttger; Sebastien Gagneux
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

5.  The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol.

Authors:  A Telenti; W J Philipp; S Sreevatsan; C Bernasconi; K E Stockbauer; B Wieles; J M Musser; W R Jacobs
Journal:  Nat Med       Date:  1997-05       Impact factor: 53.440

6.  Meropenem/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis.

Authors:  Nicolas Dauby; Inge Muylle; Françoise Mouchet; Roger Sergysels; Marie-Christine Payen
Journal:  Pediatr Infect Dis J       Date:  2011-09       Impact factor: 2.129

7.  Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis.

Authors:  O Zimhony; J S Cox; J T Welch; C Vilchèze; W R Jacobs
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

8.  Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis.

Authors:  Courtney E Maus; Bonnie B Plikaytis; Thomas M Shinnick
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

Review 9.  Tuberculosis: drug resistance, fitness, and strategies for global control.

Authors:  Erik C Böttger; Burkhard Springer
Journal:  Eur J Pediatr       Date:  2007-11-07       Impact factor: 3.183

10.  Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.

Authors:  Vija Skripconoka; Manfred Danilovits; Lea Pehme; Tarmo Tomson; Girts Skenders; Tiina Kummik; Andra Cirule; Vaira Leimane; Anu Kurve; Klavdia Levina; Lawrence J Geiter; Davide Manissero; Charles D Wells
Journal:  Eur Respir J       Date:  2012-09-27       Impact factor: 16.671

View more
  29 in total

1.  Delving into the Characteristic Features of "Menace" Mycobacterium tuberculosis Homologs: A Structural Dynamics and Proteomics Perspectives.

Authors:  Adeniyi T Adewumi; Pritika Ramharack; Opeyemi S Soremekun; Mahmoud E S Soliman
Journal:  Protein J       Date:  2020-04       Impact factor: 2.371

2.  Photoactivatable Glycolipid Probes for Identifying Mycolate-Protein Interactions in Live Mycobacteria.

Authors:  Herbert W Kavunja; Kyle J Biegas; Nicholas Banahene; Jessica A Stewart; Brent F Piligian; Jessica M Groenevelt; Caralyn E Sein; Yasu S Morita; Michael Niederweis; M Sloan Siegrist; Benjamin M Swarts
Journal:  J Am Chem Soc       Date:  2020-04-20       Impact factor: 15.419

3.  Potent 1,2,4-Triazino[5,6 b]indole-3-thioether Inhibitors of the Kanamycin Resistance Enzyme Eis from Mycobacterium tuberculosis.

Authors:  Huy X Ngo; Keith D Green; Chathurada S Gajadeera; Melisa J Willby; Selina Y L Holbrook; Caixia Hou; Atefeh Garzan; Abdelrahman S Mayhoub; James E Posey; Oleg V Tsodikov; Sylvie Garneau-Tsodikova
Journal:  ACS Infect Dis       Date:  2018-03-30       Impact factor: 5.084

4.  The Dual-Targeting Activity of the Metabolite Substrate of Para-amino Salicyclic Acid in the Mycobacterial Folate Pathway: Atomistic and Structural Perspectives.

Authors:  Clement Agoni; Pritika Ramharack; Elliasu Y Salifu; Mahmoud E S Soliman
Journal:  Protein J       Date:  2020-04       Impact factor: 2.371

5.  Strengthening the response to drug-resistant TB in Pakistan: a practice theory-informed approach.

Authors:  S Abbas; M Kermode; S Kane
Journal:  Public Health Action       Date:  2020-12-21

Review 6.  Recent Progress and Challenges for Drug-Resistant Tuberculosis Treatment.

Authors:  Filia Stephanie; Mutiara Saragih; Usman Sumo Friend Tambunan
Journal:  Pharmaceutics       Date:  2021-04-21       Impact factor: 6.321

7.  Concurrent pulmonary tuberculosis and lepromatous leprosy in a newly diagnosed HIV positive patient: a case report.

Authors:  Josiah T Masuka; Zamambo Mkhize; Somasundram Pillay; Anisa Mosam
Journal:  BMC Pulm Med       Date:  2021-06-30       Impact factor: 3.317

Review 8.  Post translational modifications in tuberculosis: ubiquitination paradox.

Authors:  Mohd Shariq; Neha Quadir; Javaid Ahmad Sheikh; Alok Kumar Singh; William R Bishai; Nasreen Z Ehtesham; Seyed E Hasnain
Journal:  Autophagy       Date:  2020-11-24       Impact factor: 16.016

9.  The Frequency and Effect of Granulocytic Myeloid-Derived Suppressor Cells on Mycobacterial Survival in Patients With Tuberculosis: A Preliminary Report.

Authors:  Malika Davids; Anil Pooran; Liezel Smith; Michele Tomasicchio; Keertan Dheda
Journal:  Front Immunol       Date:  2021-06-01       Impact factor: 7.561

10.  Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients.

Authors:  S E J van de Berg; P T Pelzer; C Mulder; S van den Hof; A J van der Land; E Abdrakhmanova; A Muhammad Ozi; M Arias; S Cook-Scalise; G Dravniece; A Gebhard; S Juneja; R Handayani; D Kappel; M Kimerling; I Koppelaar; S Malhotra; B Myrzaliev; B Nsa; J Sugiharto; N Engel
Journal:  BMC Public Health       Date:  2021-07-16       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.